โš  LIVE โ€” European Consumer Safety Watch ๐Ÿ’Š Medicines: 34 in last 7 days ๐ŸŽ Food: 1 in last 7 days ๐Ÿงธ Products: 0 in last 7 days ๐ŸŸข Monitoring: EMA ยท RASFF ยท NVWA ยท FAGG ยท FAVV ยท EFSA ยท Safety Gate โฑ Last fetch: 5 hours ago โš  LIVE โ€” European Consumer Safety Watch ๐Ÿ’Š Medicines: 34 in last 7 days ๐ŸŽ Food: 1 in last 7 days ๐Ÿงธ Products: 0 in last 7 days ๐ŸŸข Monitoring: EMA ยท RASFF ยท NVWA ยท FAGG ยท FAVV ยท EFSA ยท Safety Gate โฑ Last fetch: 5 hours ago
๐Ÿ›ก๏ธ EUSW
๐Ÿ‡ฌ๐Ÿ‡ง
๐Ÿ’Š

Zavesca

miglustat
Gaucher Disease;Niemann-Pick Diseases
โœ… Authorised
โœ…
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.

What it's used for

Zavesca is indicated for the oral treatment of adult patients with mild to moderate type-1 Gaucher disease. Zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable. Zavesca is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type-C disease.

โš ๏ธ Patient safety

No

โš ๏ธ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.